Search Browse Earnings

Kymera Therapeutics, Inc.

Nasdaq:KYMR

Biological Products, (No Diagnostic Substances)·WATERTOWN, MA

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Revenue

$78.6M

+67.8% YoY

FY 2025

Adj. EBITDA

-$162.0M

-206.1% margin

FY 2025

Net Income

-$147.0M

-187.0% margin

FY 2025

EPS (Diluted)

-$2.52

FY 2025

Stock Price

$84.06

+0.7%

2026-03-09

52W Range

$19.45 – $103.00

P/E Ratio

-33.4x

Market Cap

$6.9B

Cash

$110.0M

FY 2025

Total Debt

—

Net Cash

$110.0M

FY 2025

Enterprise Value

$6.8B

Debt / EBITDA

0.7x

FY 2025

EV / EBITDA

-41.7x

Employees

—